Non-steroidal anti-inflammatory drug use and colorectal polyps in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

American Journal of Gastroenterology

Volumn 105, Issue 12, 2010, Pages 2646-2655

  Johnson, Christine Cole ^a   Hayes, Richard B ^b,d   Schoen, Robert E ^c   Gunter, Marc J ^b,e   Huang, Wen Yi ^b  

^a HENRY FORD HOSPITAL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADENOMATOUS POLYP; ADULT; AGED; ARTICLE; BODY MASS; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; COLON POLYP; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESCENDING COLON; DISEASE ASSOCIATION; DRUG EFFECT; DRUG USE; FEMALE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RECTUM POLYP; RISK REDUCTION; SEX DIFFERENCE; SIGMOID; SIGMOIDOSCOPY; TUMOR BIOPSY; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BIOPSY; COLONIC POLYPS; FEMALE; HUMANS; IBUPROFEN; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEX FACTORS; SIGMOIDOSCOPY; UNITED STATES;

EID: 78649861297     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.349     Document Type: Article

References (58)

1. International Agency for Research on Cancer. IARC Handbook of Cancer Prevention. Non-Steroidal Anti-Infl ammatory Drugs. IARC (WHO): Lyon, 1997.
2. Dube C, Rostom A, Lewin G. et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. preventive services task force. Ann Intern Med 2007;146: 365-75.
3. Arber N, Levin B. Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology 2008;134: 1224-37.
4. Rostom A, Dube C, Lewin G et al. Nonsteroidal anti-infl ammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007;146: 376-89.
5. Peleg II, Wilcox CM. The role of eicosanoids, cyclooxygenases, and nonsteroidal anti-infl ammatory drugs in colorectal tumorigenesis and chemoprevention. J Clin Gastroenterol 2002;34: 117-25.
6. Th un MJ, Henley SJ, Patrono C. Nonsteroidal anti-infl ammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94: 252-66.
7. Baron JA, Sandler RS. Nonsteroidal anti-infl ammatory drugs and cancer prevention. Annu Rev Med 2000;51: 511-23.
8. Chan TA. Nonsteroidal anti-infl ammatory drugs, apoptosis, and coloncancer chemoprevention. Lancet Oncol 2002;3: 166-74.
9. Herendeen JM, Lindley C. Use of NSAIDs for the chemoprevention of colorectal cancer. Ann Pharmacother 2003;37: 1664-74.
10. Asano TK, McLeod RS. Non steroidal anti-infl ammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database Syst Rev 2008;4: 1-35;CD004079.
11. Harris RE, Beebe-Donk J, Doss H et al. Aspirin, ibuprofen, and other nonsteroidal anti-infl ammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 2005;13: 559-83.
12. Baron JA, Cole BF, Sandler RS et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348: 891-9.
13. Sandler RS, Halabi S, Baron JA et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348: 883-90.
14. Chan AT, Giovannucci EL, Meyerhardt JA et al. Long-term use of aspirin and nonsteroidal anti-infl ammatory drugs and risk of colorectal cancer. JAMA 2005;294: 914-23.
15. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007;369: 1603-13.
16. Logan RF, Grainge MJ, Shepherd VC et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008;134: 29-38.
17. Tangrea JA, Albert PS, Lanza E et al. Non-steroidal anti-infl ammatory drug use is associated with reduction in recurrence of advanced and nonadvanced colorectal adenomas (United States). Cancer Causes Control 2003;14: 403-11.
18. Asano TK, McLeod RS. Nonsteroidal anti-infl ammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review. Dis Colon Rectum 2004;47: 665-73.
19. Garcia Rodriguez LA, Huerta-Alvarez C. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinfl ammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology 2000;11: 376-81.
20. Zapolska-Downar D, Naruszewicz M. A pleiotropic antiatherogenic action of ibuprofen. Med Sci Monit 2001;7: 837-41.
21. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998;90: 1529-36.
22. Steinbach G, Lynch PM, Phillips RK et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342: 1946-52.
23. Din FV, Stark LA, Dunlop MG. Aspirin-induced nuclear translocation of NFkappaB and apoptosis in colorectal cancer is independent of p53 status and DNA mismatch repair profi ciency. Br J Cancer 2005;92: 1137-43.
24. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-infl ammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006;6: 130-40.
25. Kune G. Commentary: aspirin and cancer prevention. Int J Epidemiol 2007;36: 957-9.
26. Arber N. Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point. Cancer Epidemiol Biomarkers Prev 2008;17: 1852-7.
27. Jass JR. Hyperplastic polyps and colorectal cancer: is there a link? Clin Gastroenterol Hepatol 2004;2: 1-8.
28. Weissfeld JL, Schoen RE, Pinsky PF et al. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst 2005;97: 989-97.
29. Beral V, Banks E, Reeves G. Evidence from randomised trials on the longterm effects of hormone replacement therapy. Lancet 2002;360: 942-4.
30. Purdue MP, Mink PJ, Hartge P et al. Hormone replacement therapy, reproductive history, and colorectal adenomas: data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial (United States). Cancer Causes Control 2005;16: 965-73.
31. Chen MJ, Longnecker MP, Morgenstern H et al. Recent use of hormone replacement therapy and the prevalence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 1998;7: 227-30.
32. Terry MB, Neugut AI, Bostick RM et al. Risk factors for advanced colorectal adenomas: a pooled analysis. Cancer Epidemiol Biomarkers Prev 2002;11: 622-9.
33. Giovannucci E, Egan KM, Hunter DJ et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333: 609-14.
34. Imperiale TF. Aspirin and the prevention of colorectal cancer. N Engl J Med 2003;348: 879-80.
35. Kanik E, Canbaz H, Colak T et al. Chemopreventive effect of nonsteroidal anti-infl ammatory drugs on the development of a new colorectal polyp or adenoma in a high-risk population: a meta-analysis. Curr Therap Res-Clin Exp 2004;65: 345-52.
36. Larsson SC, Giovannucci E, Wolk A. Long-term aspirin use and colorectal cancer risk: a cohort study in Sweden. Br J Cancer 2006;95: 1277-9.
37. Collet JP, Sharpe C, Belzile E et al. Colorectal cancer prevention by nonsteroidal anti-infl ammatory drugs: effects of dosage and timing. Br J Cancer 1999;81: 62-8.
38. Chan AT, Giovannucci EL, Meyerhardt JA et al. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 2008;134: 21-8.
39. Lieberman DA, Prindiville S, Weiss DG et al. Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. JAMA 2003;290: 2959-67.
40. Benamouzig R, Deyra J, Martin A et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003;125: 328-36.
41. Van Der Ouderaa FJ, Buytenhek M, Nugteren D et al. Acetylation of prostaglandin endoperoxide synthetase with acetylsalicylic acid. Eur J Biochem 1980;109: 1-8.
42. Th un MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325: 1593-6.
43. Sangha S, Yao M, Wolfe MM. Non-steroidal anti-infl ammatory drugs and colorectal cancer prevention. Postgrad Med J 2005;81: 223-7.
44. Sturmer T, Buring JE, Lee IM et al. Colorectal cancer aft er start of nonsteroidal anti-infl ammatory drug use. Am J Med 2006;119: 494-502.
45. Cook NR, Lee IM, Gaziano JM et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294: 47-55.
46. Ridker PM, Cook NR, Lee IM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352: 1293-304.
47. Levin RI. The puzzle of aspirin and sex. N Engl J Med 2005;352: 1366-8.
48. Kaiser J. Gender in the pharmacy: does it matter? Science 2005;308: 1572.
49. Chan AT, Giovannucci EL, Schernhammer ES et al. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med 2004;140: 157-66.
50. Giovannucci E, Rimm EB, Stampfer MJ et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121: 241-6.
51. Kim S, Baron JA, Mott LA et al. Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States). Cancer Causes Control 2006;17: 1299-304.
52. Hoffmeister M, Chang-Claude J, Brenner H. Do older adults using NSAIDs have a reduced risk of colorectal cancer? Drugs Aging 2006;23: 513-23.
53. Jankowski J, Hunt R. Cyclooxygenase-2 inhibitors in colorectal cancer prevention: counterpoint. Cancer Epidemiol Biomarkers Prev 2008;17: 1858-61.
54. Bertagnolli MM, Eagle CJ, Zauber AG et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355: 873-84.
55. Sansbury LB, Millikan RC, Schroeder JC et al. Use of nonsteroidal antiinfl ammatory drugs and risk of colon cancer in a population-based, case-control study of African Americans and Whites. Am J Epidemiol 2005;162: 548-58.
56. Pinsky PF, Miller A, Kramer BS et al. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol 2007;165: 874-81.
57. Lamerato LE, Marcus PM, Jacobsen G et al. Recruitment in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial: the First Phase of Recruitment at Henry Ford Health System. Cancer Epidemiol Biomarkers Prev 2008;17: 827-33.
58. Ulrich CM, Whitton J, Yu JH et al. PTGS2 (COX-2)? 765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-infl ammatory drugs. Cancer Epidemiol Biomarkers Prev 2005;14: 616-9.